Checkpoint inhibitor therapy and psoriasis: a case series

Checkpoint inhibitor therapy (CPI) has significantly improved overall survival in several cancers, including metastatic melanoma and in the adjuvant setting. Cutaneous immune-related adverse events secondary to CPI are commonly observed; however, the development of psoriasis or exacerbation of exist...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental dermatology Vol. 48; no. 3; pp. 254 - 256
Main Authors Hussain, Khawar, Kanji, Alpa, Zaheri, Shirin, Malek, Dalila, Terlizzo, Monica, Weir, Justin, Turajlic, Samra, Fearfield, Louise
Format Journal Article
LanguageEnglish
Published England 01.03.2023
Subjects
Humans
Nivolumab
Psoriasis - therapy
Online AccessGet full text

Cover

More Information
Summary:Checkpoint inhibitor therapy (CPI) has significantly improved overall survival in several cancers, including metastatic melanoma and in the adjuvant setting. Cutaneous immune-related adverse events secondary to CPI are commonly observed; however, the development of psoriasis or exacerbation of existing psoriasis has not been widely reported and management can be challenging.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0307-6938
1365-2230
DOI:10.1093/ced/llac095